HOME >> BIOLOGY >> NEWS
March of Dimes awards $250,000 prize to research pioneer

WHITE PLAINS, N.Y. MAY 1, 2006 -- For explaining how a tiny protein plays a major role in our lives by helping to regulate many crucial processes in human cells, Alexander Varshavsky, Ph.D., has been chosen as the 2006 recipient of the March of Dimes Prize in Developmental Biology, to be awarded May 1 in San Francisco, California.

The March of Dimes Prize is a cash award of $250,000 and a silver medal in the design of the Roosevelt dime, in honor of President Franklin Delano Roosevelt, who founded the March of Dimes.

Dr. Varshavsky, the Howard and Gwen Laurie Smits Professor of Cell Biology in the Division of Biology at the California Institute of Technology, has been credited by his peers with co-founding the field of ubiquitin research and ushering it into the age of molecular genetics. His pioneering studies in the 1980s brought to light the remarkably diverse and important biological functions of the ubiquitin system.

Ubiquitin (from the Latin ubique meaning "everywhere," the source of the word "ubiquitous"), is a protein found in every cell of all living things, from yeast to human beings. It attaches itself to many other proteins in cells specifically those proteins that have outlived their purpose, or are abnormal, or must be destroyed to regulate their levels in a cell. Ubiquitin marks these proteins for destruction by a protein-degrading molecular "machine" called the proteasome.

Dr. Varshavsky's laboratory discovered that ubiquitin plays important roles in the cell cycle, DNA repair, protein synthesis, transcriptional regulation, and responses to stress. Dr. Varshavsky and coworkers also discovered "degradation" signals in short-lived proteins, the source of ubiquitin's selectivity as well as a fundamental property of the ubiquitin system that makes it possible to remodel multi-subunit proteins by destroying them partially, "one subunit at a time." His work revealed that the regulation of cells through selective
'"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Birth Defects Foundation
10-Apr-2006


Page: 1 2

Related biology news :

1. March of the giant penguins
2. March of Dimes awards $250K prize to stem cell research, reproductive biology pioneers
3. ACS News Service Weekly PressPac -- March 28, 2007
4. ACS News Service Weekly PressPac -- March 21, 2007
5. National Academies advisory: March 27 release of report on metagenomics
6. JCI table of contents -- March 22, 2007
7. Other highlights from the March 21 JNCI
8. Story tips from the Department of Energys Oak Ridge National Laboratory, March 2007
9. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
10. ACS News Service Weekly PressPac -- March. 14, 2007
11. Pioneering researcher Dr. Kenneth Lyons Jones receives genetics award from March of Dimes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: March Dimes awards prize research pioneer

(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: